Company Overview - TKO Group Holdings (TKO) is expected to report a year-over-year increase in earnings due to higher revenues for the quarter ended June 2025, with a consensus outlook indicating a quarterly earnings of $1.23 per share, representing a +70.8% change, and revenues expected to be $1.2 billion, up 41.3% from the previous year [1][3]. Earnings Estimates and Revisions - The consensus EPS estimate has been revised 5.69% higher over the last 30 days, reflecting a reassessment by covering analysts [4]. - The Most Accurate Estimate for TKO Group is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -48.11%, indicating a bearish outlook on the company's earnings prospects [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative Earnings ESP reading indicates the likely deviation of actual earnings from the consensus estimate, with a positive reading being a strong predictor of an earnings beat [9][10]. - TKO Group currently holds a Zacks Rank of 3, making it difficult to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, TKO Group had an earnings surprise of +43.75%, with actual earnings of $0.69 per share compared to an expected $0.48 [13]. - Over the last four quarters, TKO Group has beaten consensus EPS estimates two times [14]. Industry Context - In the Zacks Film and Television Production and Distribution industry, Cinemark Holdings (CNK) is expected to post earnings of $0.78 per share for the same quarter, indicating a year-over-year change of +143.8%, with revenues expected to be $947.59 million, up 29.1% [18][19].

Core Viewpoint - Aclaris Therapeutics (ACRS) is anticipated to report a year-over-year increase in earnings despite lower revenues, which could significantly influence its stock price based on actual results compared to estimates [1][2]. Financial Performance Expectations - The consensus estimate indicates Aclaris is expected to post a quarterly loss of $0.13 per share, reflecting a year-over-year change of +13.3% [3]. - Revenues are projected to be $1.55 million, representing a decline of 44% from the same quarter last year [3]. Estimate Revisions and Predictions - Over the last 30 days, the consensus EPS estimate has been revised 1.41% higher, indicating a positive reassessment by analysts [4]. - Aclaris has an Earnings ESP of +10.00%, suggesting analysts have become more optimistic about the company's earnings prospects [12]. Historical Performance and Trends - In the last reported quarter, Aclaris was expected to incur a loss of $0.17 per share but actually reported a loss of $0.12, resulting in a positive surprise of +29.41% [13]. - Over the past four quarters, Aclaris has exceeded consensus EPS estimates three times [14]. Industry Context - Another player in the Zacks Medical - Drugs industry, Zoetis (ZTS), is expected to report earnings of $1.61 per share for the same quarter, indicating a year-over-year change of +3.2% [18]. - Zoetis's revenues are expected to reach $2.4 billion, up 1.7% from the previous year [18].

Core Viewpoint - The market anticipates Adient (ADNT) to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Adient is expected to post quarterly earnings of $0.47 per share, reflecting a year-over-year increase of +46.9%, while revenues are projected to be $3.56 billion, down 4.2% from the previous year [3]. - The consensus EPS estimate has been revised 15.28% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Most Accurate Estimate for Adient is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +6.47%, suggesting a strong likelihood of beating the consensus EPS estimate [12]. - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. Historical Performance - In the last reported quarter, Adient exceeded the expected earnings of $0.36 per share by delivering $0.69, resulting in a surprise of +91.67% [13]. - Over the past four quarters, Adient has beaten consensus EPS estimates three times [14]. Industry Context - Another player in the automotive sector, LCI (LCII), is expected to report earnings of $2.22 per share for the same quarter, indicating a year-over-year decline of -7.5%, with revenues expected to be $1.08 billion, up 2.2% [18]. - LCI's consensus EPS estimate has remained unchanged, but a higher Most Accurate Estimate has led to an Earnings ESP of +4.62%, indicating a likely earnings beat [19].

Core Viewpoint - Acadia Pharmaceuticals is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended June 2025, with the actual results being crucial for its near-term stock price movement [1][2]. Financial Expectations - The consensus estimate for Acadia's quarterly earnings is $0.14 per share, reflecting a year-over-year decrease of 30%. Revenues are projected to be $260.28 million, representing a 7.6% increase from the previous year [3]. - The consensus EPS estimate has been revised down by 1.59% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Potential - Acadia's Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +17.43%, suggesting a bullish outlook from analysts [12]. - The stock holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Acadia was expected to post earnings of $0.10 per share but exceeded this with earnings of $0.11, achieving a surprise of +10.00% [13]. - Over the past four quarters, Acadia has surpassed consensus EPS estimates three times [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, TG Therapeutics is expected to report earnings of $0.32 per share for the same quarter, indicating a year-over-year increase of 700%, with revenues projected at $136.04 million, up 85.2% from the previous year [18][19].

The market expects Arcutis Biotherapeutics, Inc. (ARQT) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 6, might help the stock move higher if these key n ...

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This company is expected to post quarterly earnings of $0.10 per share in its upcoming report, which represents a year-over-year change of +42.9%. Revenues are expected to be $103.56 million, up 11% from the year-ago quarter. The market expects Certa ...

Core Viewpoint - Capri Holdings (CPRI) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2025, with the consensus outlook being crucial for assessing the company's earnings picture [1][3]. Earnings Expectations - The upcoming earnings report is anticipated to show earnings of $0.13 per share, reflecting a significant year-over-year increase of +225%, while revenues are projected to decline by 27.4% to $774.5 million [3]. - The stock price may rise if the actual earnings exceed expectations, whereas a miss could lead to a decline in stock value [2]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 3.54%, indicating a collective reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Capri Holdings is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.49%, suggesting a bearish outlook from analysts [12]. Historical Performance - Capri Holdings has not been able to beat consensus EPS estimates in the last four quarters, with a notable surprise of -2,962.50% in the last reported quarter where a loss of $0.16 per share was expected, but the actual loss was -$4.90 [13][14]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a favorable Zacks Rank [10]. - Capri Holdings currently holds a Zacks Rank of 5 (Strong Sell), which complicates the prediction of an earnings beat [12]. Conclusion - Capri Holdings does not appear to be a compelling candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17].

Chord Energy Corporation (CHRD) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 6, might help the stock move higher if these key numbers are better th ...

Core Viewpoint - The market anticipates Mirum Pharmaceuticals, Inc. (MIRM) will report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Financial Expectations - The consensus estimate indicates a quarterly loss of $0.31 per share, reflecting a year-over-year improvement of +40.4%. Revenues are projected to reach $108.4 million, representing a 39.2% increase from the same quarter last year [3]. - The consensus EPS estimate has been revised 6.92% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Potential - The Most Accurate Estimate for Mirum Pharmaceuticals is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +8.65%, suggesting a strong likelihood of beating the consensus EPS estimate [12]. - Historical performance shows that Mirum Pharmaceuticals has beaten consensus EPS estimates in two out of the last four quarters, with a notable surprise of +23.08% in the last reported quarter [13][14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Tango Therapeutics, Inc. (TNGX) is expected to report a loss of $0.35 per share for the same quarter, indicating a year-over-year decline of -45.8%. Revenue expectations for Tango are $6.19 million, down 68.9% from the previous year [18][19]. - Tango Therapeutics has a Zacks Rank of 2 (Buy) and an Earnings ESP of +0.57%, suggesting a likelihood of surpassing the consensus EPS estimate [20].

The market expects Watts Water (WTS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 6, might help the stock move higher if these key numbers are better t ...